Mesoblast to Host First Quarter Financial Results Conference Call and Webcast on 16 December 2015

MELBOURNE, Australia and NEW YORK, Dec. 15, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) today announced it will report financial results for the quarter ended 30 September 2015 after the close of the Nasdaq market on Wednesday 16 December. Mesoblast management will host a conference call to review results and provide a corporate update beginning at 5:00 pm Eastern Time on Wednesday, 16 December / 09:00 am Australian Eastern Daylight Time on Thursday, 17 December.

To access the call, dial 855-298-3404 (toll-free US), 1800-801-825 (toll-free Australia) or +1 631-514-2526 (outside of the US). The passcode is 6205376. The conference call will be accompanied by a slide presentation. Please log in approximately 10 minutes prior to the scheduled start time. The live webcast will be available at http://edge.media-server.com/m/p/ajsucdcx/lan/en and http://investorsmedia.mesoblast.com/phoenix.zhtml?c=187006&p=irol-calendar. The archived webcast will be available in the Events and Presentations section of the Investor page on the Company's website.

About Mesoblast
Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) is a global leader in cell-based medicines. The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates. Mesoblast’s allogeneic, ‘off-the-shelf’ cell product candidates target advanced stages of diseases where there are highly unmet medical needs, including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncology/hematology conditions.

For further information, please contact: Michael Schuster Head, Investor Relations Mesoblast Limited T: 212-880-2060 E: michael.schuster@mesoblast.com Julie Meldrum Global Head, Corporate Communications Mesoblast Limited T: +61 3 9639 6036 E: julie.meldrum@mesoblast.com

Source:Mesoblast Limited